(RTTNews) - Japanese drugmaker Astellas Pharma Inc. (ALPMY) announced on Thursday that it has entered into a clinical trial collaboration and supply agreement with Immuneering Corp. (IMRX) to evaluate combination therapies for pancreatic cancer patients, whose tumors express CLDN
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.